Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses
James A Wiley, Laura E Richert, Steve D Swain, Ann Harmsen, Dale L Barnard, Troy D Randall, Mark Jutila, Trevor Douglas, Chris Broomell, Mark Young, Allen Harmsen, James A Wiley, Laura E Richert, Steve D Swain, Ann Harmsen, Dale L Barnard, Troy D Randall, Mark Jutila, Trevor Douglas, Chris Broomell, Mark Young, Allen Harmsen
Abstract
Background: Destruction of the architectural and subsequently the functional integrity of the lung following pulmonary viral infections is attributable to both the extent of pathogen replication and to the host-generated inflammation associated with the recruitment of immune responses. The presence of antigenically disparate pulmonary viruses and the emergence of novel viruses assures the recurrence of lung damage with infection and resolution of each primary viral infection. Thus, there is a need to develop safe broad spectrum immunoprophylactic strategies capable of enhancing protective immune responses in the lung but which limits immune-mediated lung damage. The immunoprophylactic strategy described here utilizes a protein cage nanoparticle (PCN) to significantly accelerate clearance of diverse respiratory viruses after primary infection and also results in a host immune response that causes less lung damage.
Methodology/principal findings: Mice pre-treated with PCN, independent of any specific viral antigens, were protected against both sub-lethal and lethal doses of two different influenza viruses, a mouse-adapted SARS-coronavirus, or mouse pneumovirus. Treatment with PCN significantly increased survival and was marked by enhanced viral clearance, accelerated induction of viral-specific antibody production, and significant decreases in morbidity and lung damage. The enhanced protection appears to be dependent upon the prior development of inducible bronchus-associated lymphoid tissue (iBALT) in the lung in response to the PCN treatment and to be mediated through CD4+ T cell and B cell dependent mechanisms.
Conclusions/significance: The immunoprophylactic strategy described utilizes an infection-independent induction of naturally occurring iBALT prior to infection by a pulmonary viral pathogen. This strategy non-specifically enhances primary immunity to respiratory viruses and is not restricted by the antigen specificities inherent in typical vaccination strategies. PCN treatment is asymptomatic in its application and importantly, ameliorates the damaging inflammation normally associated with the recruitment of immune responses into the lung.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Belshe R, Lee MS, Walker RE, Stoddard J, Mendelman PM. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev. Vaccines. 2004;3:643–654.
- Treanor J, Wu H, Kiang H, Topham DJ. Immune responses to vaccinia and influenza elicited during primary versus recent or distant secondary smallpox vaccination of adults. Vaccine. 2006;24:6913–6923.
- Minne A, Huaux F, Jaworska J, Rha R-D, Hamelmann E, et al. Safety evaluation of pulmonary influenza vaccination in healthy and “asthmatic” mice. Vaccine. 2008;26:2360–2368.
- Chen HD, Fraire AE, Joris I, Welsh RM, Selin LK. Specific history of heterologous virus infections determines anti-viral immunity and immunopathology in the lung. Am J Pathol. 2003;163:1341–1355.
- Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M, et al. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006;116:3183–3194.
- Moyron-Quiroz JE, Rangel-Moreno J, Hartson L, Kusser K, Tighe MP, et al. Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity. 2006;25:643–654.
- Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, Hartson L, Sprague F, et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med. 2004;10:927–934.
- Kim KK, Kim R, Kim SH. Crystal structure of a small heat-shock protein. Nature. 1998;394:595–599.
- Carragher DM, Rangel-Moreno J, Randall TD. Ectopic lymphoid tissues and local immunity. Semin Immunol. 2008;20:26–42.
- Randall TD, Carragher DM, Rangel-Moreno J. Development of secondary lymphoid organs. Annu Rev Immunol. 2008;26:627–650.
- Drent M, Cobben NAM, Henderson RF, Wouters EFM, van Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J. 1996;9:1736–1742.
- Wiley JA, Harmsen AG. Bone marrow-derived cells are required for the induction of a pulmonary inflammatory response mediated by CD40 ligation. Am J Pathol. 1999;154:919–926.
- Rosenberg HF, Domachowske JB. Pneumonia virus of mice: severe respiratory infection in a natural host. Immunol Lett. 2008;118:6–12.
- Karaolis DKR, Newstead MW, Zeng X, Hyodo M, Hayakawa Y, et al. Cyclic Di-GMP stimulates protective innate immunity in bacterial pneumonia. Infect Immun. 2007;75:4942–4950.
- Poltorak A, He X, Smirnova I, Liu M-Y, Huffel CV, et al. Defective LPS signalling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085–2088.
- Humphreys IR, Walzl G, Edwards L, Rae A, Hill S, et al. A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J Exp Med. 2003;198:1237–1242.
- Flenniken ML, Willits DA, Harmsen AL, Liepold LO, Harmsen AG, et al. Melanoma and lymphocyte cell-specific targeting incorporated into a heat shock protein cage architecture. Chem Biol. 2006;13:161–170.
- Wiley JA, Tighe MP, Harmsen AG. Upper respiratory tract resistance to influenza infection is not prevented by the absence of either nasal-associated lymphoid tissue or cervical lymph nodes. J Immunol. 2005;175:3186–3196.
- Wiley JA, Cerwenka A, Harkema JR, Dutton RW, Harmsen AG. Production of interferon-γ by influenza hemagglutinin-specific CD8 effector T cells influences the development of pulmonary immunopathology. Am J Pathol. 2001;158:119–130.
Source: PubMed